GLUE RSI Chart
Last 7 days
6.8%
Last 30 days
-10.7%
Last 90 days
-13.1%
Trailing 12 Months
-6.5%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 28, 2021 | versant venture capital vi, l.p. | acquired | - | - | 6,515,870 | - |
Jun 28, 2021 | cormorant asset management, lp | acquired | - | - | 2,602,200 | - |
Jun 28, 2021 | behbahani ali | acquired | - | - | 6,642,300 | - |
Jun 28, 2021 | behbahani ali | bought | 19,950,000 | 19.00 | 1,050,000 | - |
Jun 28, 2021 | landsman liza | acquired | - | - | 6,642,300 | - |
Jun 28, 2021 | landsman liza | bought | 19,950,000 | 19.00 | 1,050,000 | - |
Jun 28, 2021 | makhzoumi mohamad | acquired | - | - | 6,642,300 | - |
Jun 28, 2021 | makhzoumi mohamad | bought | 19,950,000 | 19.00 | 1,050,000 | - |
Jun 28, 2021 | versant venture capital vi, l.p. | acquired | - | - | 1,940,040 | - |
Jun 28, 2021 | cormorant asset management, lp | bought | 11,400,000 | 19.00 | 600,000 | - |
Which funds bought or sold GLUE recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | COMERICA BANK | unchanged | - | 1,177 | 5,929 | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -68.66 | -243,291 | 156,249 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.03 | -6,430 | 21,933 | -% |
May 15, 2024 | WELLINGTON MANAGEMENT GROUP LLP | new | - | 850,561 | 850,561 | -% |
May 15, 2024 | UBS OCONNOR LLC | sold off | -100 | -249,996 | - | -% |
May 15, 2024 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | unchanged | - | 420 | 2,115 | -% |
May 15, 2024 | BAKER BROS. ADVISORS LP | unchanged | - | 6,882,530 | 34,658,500 | 0.44% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 122 | 677,550 | 1,057,680 | -% |
May 15, 2024 | SPHERA FUNDS MANAGEMENT LTD. | sold off | -100 | -274,087 | - | -% |
May 15, 2024 | NEA Management Company, LLC | unchanged | - | 10,769,200 | 54,230,700 | 3.37% |
Unveiling Monte Rosa Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Monte Rosa Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Monte Rosa Therapeutics, Inc. News
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | -12.2% | 267 | 304 | 252 | 279 | 309 | 342 | 358 | 365 | 346 | 366 | 384 | 369 | 49.00 |
Current Assets | -15.7% | 199 | 236 | 183 | 208 | 241 | 276 | 295 | 297 | 320 | 349 | 371 | 358 | 44.00 |
Cash Equivalents | -18.3% | 105 | 128 | 59.00 | 47.00 | 52.00 | 55.00 | 112 | 104 | 138 | 351 | 367 | 357 | 43.00 |
Net PPE | 0.7% | 34.00 | 34.00 | 35.00 | 35.00 | 33.00 | 27.00 | 19.00 | 15.00 | 13.00 | 12.00 | 12.00 | 9.00 | 5.00 |
Liabilities | -8.3% | 114 | 125 | 68.00 | 65.00 | 65.00 | 71.00 | 67.00 | 63.00 | 20.00 | 19.00 | 15.00 | 12.00 | 30.00 |
Current Liabilities | -11.4% | 41.00 | 47.00 | 23.00 | 19.00 | 21.00 | 26.00 | 22.00 | 15.00 | 12.00 | 17.00 | 13.00 | 11.00 | 29.00 |
Shareholder's Equity | -14.9% | 153 | 179 | 185 | 214 | 244 | 271 | 291 | 302 | 326 | 348 | 369 | 357 | 49.00 |
Retained Earnings | -8.7% | -397 | -365 | -332 | -297 | -262 | -230 | -199 | -172 | -145 | -122 | -98.60 | -78.76 | -48.08 |
Additional Paid-In Capital | 1.0% | 553 | 548 | 519 | 513 | 508 | 504 | 493 | 477 | 474 | 472 | 470 | 437 | 0.00 |
Shares Outstanding | 0.1% | 50.00 | 50.00 | 50.00 | 50.00 | 49.00 | 49.00 | 47.00 | 47.00 | 47.00 | 47.00 | 18.00 | 5.00 | 2.00 |
Float | - | - | - | - | 234 | - | - | - | 303 | - | - | - | 655 | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -228.8% | -38,165 | 29,634 | -24,706 | -25,324 | -23,406 | -23,961 | -20,600 | -20,501 | -27,404 | -14,172 | -17,794 | -13,582 | -13,815 | - | - | - |
Share Based Compensation | 19.6% | 4,873 | 4,074 | 4,468 | 4,153 | 3,974 | 3,326 | 3,214 | 2,873 | 2,251 | 1,856 | 2,073 | 1,019 | 252 | - | - | - |
Cashflow From Investing | -31.1% | 9,853 | 14,297 | 35,628 | 18,550 | 20,326 | -53,939 | 29,489 | -14,249 | -180,520 | -3,047 | -1,688 | -2,701 | -2,217 | - | - | - |
Cashflow From Financing | -99.0% | 246 | 25,173 | 1,101 | 1,200 | 18.00 | 20,434 | -217 | 96.00 | 153 | -135 | 29,456 | 205,472 | 142,769 | - | - | - |
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Collaboration Revenue | $ 1,064 | $ 0 |
Operating expenses: | ||
Research and development | 27,026 | 26,755 |
General and administrative | 8,985 | 7,504 |
Total operating expenses | 36,011 | 34,259 |
Loss from operations | (34,947) | (34,259) |
Other income (expense): | ||
Interest income | 2,442 | 2,437 |
Foreign currency exchange gain (loss), net | 620 | (85) |
Loss on sale of marketable securities | 0 | (131) |
Total other income | 3,062 | 2,221 |
Net loss before income taxes | (31,885) | (32,038) |
Provision for income taxes | (83) | 0 |
Net loss | $ (31,968) | $ (32,038) |
Net loss per share-basic | $ (0.53) | $ (0.65) |
Net loss per share-diluted | $ (0.53) | $ (0.65) |
Weighted-average number of shares outstanding used in computing net loss per common share-basic | 60,156,187 | 49,347,473 |
Weighted-average number of shares outstanding used in computing net loss per common share-diluted | 60,156,187 | 49,347,473 |
Other comprehensive income (loss): | ||
Provision for pension benefit obligation | $ 35 | $ 14 |
Unrealized gain (loss) on available-for-sale securities | (4) | 345 |
Comprehensive loss | $ (31,937) | $ (31,679) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 99,752 | $ 128,101 |
Marketable securities | 93,140 | 104,312 |
Other receivables | 601 | 505 |
Prepaid expenses and other current assets | 5,543 | 3,294 |
Total current assets | 199,036 | 236,212 |
Property and equipment, net | 34,036 | 33,803 |
Operating lease right-of-use assets | 28,422 | 28,808 |
Restricted cash | 4,863 | 4,580 |
Other long-term assets | 389 | 352 |
Total assets | 266,746 | 303,755 |
Current liabilities: | ||
Accounts payable | 6,828 | 11,152 |
Total other current liabilities | 10,713 | 14,600 |
Current deferred revenue | 20,407 | 17,678 |
Current portion of operating lease liability | 3,345 | 3,162 |
Total current liabilities | 41,293 | 46,592 |
Deferred revenue, net of current | 28,529 | 32,323 |
Defined benefit plan liability | 2,568 | 2,713 |
Operating lease liability | 41,837 | 42,877 |
Total liabilities | 114,227 | 124,505 |
Commitments and contingencies (Note 8) | ||
Stockholders' equity | ||
Preferred stock, $0.0001 par value, 10,000,000 shares authorized | 0 | 0 |
Common stock, $0.0001 par value; 500,000,000 shares authorized, 50,210,309 shares issued and 50,200,304 shares outstanding as of March 31, 2024; and 50,154,929 shares issued and 50,140,233 shares outstanding as of December 31, 2023 | 5 | 5 |
Additional paid-in capital | 553,063 | 547,857 |
Accumulated other comprehensive loss | (2,693) | (2,724) |
Accumulated deficit | (397,856) | (365,888) |
Total stockholders' equity | 152,519 | 179,250 |
Total liabilities and stockholders' equity | $ 266,746 | $ 303,755 |